Photo: biohimik.ru
The oral form of Areplivir is already included in the current guidelines for both outpatient and inpatient stages.
–
–
Full-scale production of Areplivir on the basis of Biochemist AO and its delivery to medical institutions in Russia will begin in December.
Russia has developed the first direct-acting injectable drug for the treatment of COVID-19 coronavirus called Areplivir. He passed registration and by the end of 2021 will begin to enter hospitals. On Friday, November 12, reports TASS with reference to the developer – GK Promomed.
“The first domestic direct-acting intravenous antiviral drug Areplivir (favipiravir) received a registration certificate and will be delivered to hospitals in all regions by the end of the year. With its development, Promomed Group responded to the urgent need of domestic health care for hospital COVID-19 therapy,” the statement said.
Full-scale production of the drug on the basis of JSC Biochemist and its delivery to medical institutions in Russia will begin in December 2021. A clinical study led by Academician of the Russian Academy of Sciences Dmitry Pushkar confirmed the effectiveness and safety of the new drug when used in hospitals.
The oral form of Areplivir is included in the current guidelines for both outpatient and inpatient stages. It is expected that the injectable form will also be included in the recommendations as more effective for the treatment of hospitalized patients.
The final decision will be made by the Ministry of Health of the Russian Federation at the next revision of temporary guidelines for the prevention, diagnosis and treatment of a new coronavirus infection.
As a reminder, this week the daily COVID death rate in Russia for the first time exceeded 1200 people… The country has a catastrophic situation with coronavirus, although Russia was the first in the world to announce the creation of a vaccine against this infection.
News from Correspondent.net in Telegram. Subscribe to our channel https://t.me/korrespondentnet
– .
